Language

CAS No. 253128-41-5 |Eribulin

Name: Eribulin CAS No. 253128-41-5 MF:C40H59NO11 MW:729.9 Purity:97% Package: 10g,25g,50g,100g,250g Worldwide Delivery

Categories：

Biochemicals

Email：sale06@alfachem.cn

Inquiry

Chat Now

Product introduction

Introduction and application of CAS No. 253128-41-5 |Eribulin

Synonyms:B1939;

E7389;

ER086526;

US-DMFNo.:035118;

DMFNo.:035118;

EribulinUSP/EP/BP;

Specification:

ITEMS	SPECIFICATION
CAS	253128-41-5
MF	C40H59NO11
MW	729.9
Density	1.29±0.1 g/cm3
Acidity coefficient	12.56±0.35
Solubility	Soluble in dimethyl sulfoxide
Form	Power
Storage condition	Store at -20°C

Eribulin is a derivative of the macrolide compound halichondrinB extracted from the marine sponge Halichondriaokadai. It is a chemically active substance. Its mechanism of medicinal action is to inhibit mitosis by directly binding to tubulin, inhibiting the growth of microtubules and inhibiting the growth of cancer cells to exert a therapeutic effect.

The clinical medicinal ingredient of this drug is eribulin mesylate, with the trade name Halaven. It was developed by Eisai Company of Japan and was first launched in the United States on November 15, 2010. The U.S. Food and Drug Administration (FDA) approved Halaven (A Eribulin sulfonate) is used to treat metastatic breast cancer patients who have received at least two chemotherapy treatments for advanced disease. The drug was subsequently launched in Singapore, the European Union, Switzerland, Japan and other countries.

Indications:

Eribulin is suitable for patients with metastatic breast cancer who have received at least 2 previous chemotherapy regimens (chemotherapy regimens based on anthracyclines and taxanes).

Package and transportation :

Package: 10g,25g,50g,100g,250g